MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$651,000K
Net Income
$371,400K
Net Profit Margin
57.05%
EPS
$13.85
Unit: Thousand (K) dollars
Revenue Breakdown
Clinical Diagnostics
Life Science
Revenue Breakdown
US
Europe
Asia Pacific
Americas
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net sales
651,000
592,100
693,200
653,000
Cost of goods sold
305,200
282,700
348,000
309,600
Gross profit
345,800
309,400
345,200
343,400
Selling, general and administrative expense
212,000
212,400
221,000
206,800
Research and development expense
61,200
62,900
70,300
71,300
Impairment of purchased intangibles and related items, net
-
-
172,800
-
Segment profit (gain)
72,600
34,100
-118,900
65,300
Interest expense
12,100
12,300
12,100
12,300
Foreign exchange (gains) losses, net
200
2,400
2,100
2,900
(gains) losses from change in fair market value of equity securities and loan receivable
-
-
1,029,500
-
Marketable securities, unrealized (gain) loss
458,000
-738,200
-
-495,300
Other nonoperating income (expense)
23,400
24,200
28,600
8,300
Income (loss) from continuing operations before income taxes, noncontrolling interest
542,100
-689,800
929,200
-431,100
(provision) benefit for income taxes
170,700
-162,700
209,200
-89,200
Net income attributable to bio-rad
371,400
-527,100
720,000
-341,900
Basic EPS
13.89
-19.55
26.704
-12.7
Diluted EPS
13.85
-19.55
26.649
-12.7
Basic Average Shares
26,746,000
26,958,000
26,962,000
26,923,000
Diluted Average Shares
26,814,000
26,958,000
27,018,000
26,923,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
1
2
Clinical Diagnostics
$399,000K
(2.62%↑ Y/Y)
Life Science
$252,000K
(-4.11%↓ Y/Y)
Net sales
$651,000K
(-0.09%↓ Y/Y)
Gross profit
$345,800K
(0.14%↑ Y/Y)
Cost of goods sold
$305,200K
(-0.36%↓ Y/Y)
Marketable securities,
unrealized (gain) loss
$458,000K
(36.96%↑ Y/Y)
Segment profit (gain)
$72,600K
(-5.84%↓ Y/Y)
Other nonoperating
income (expense)
$23,400K
(44.44%↑ Y/Y)
Selling, general and
administrative expense
$212,000K
(2.07%↑ Y/Y)
Research and development
expense
$61,200K
(1.16%↑ Y/Y)
Foreign exchange
(gains) losses, net
$200K
(118.18%↑ Y/Y)
Income (loss) from
continuing operations...
$542,100K
(30.94%↑ Y/Y)
Interest expense
$12,100K
(-3.97%↓ Y/Y)
Net income
attributable to bio-rad
$371,400K
(16.87%↑ Y/Y)
(provision) benefit for
income taxes
$170,700K
(77.44%↑ Y/Y)
Buy us a coffee
BIO-RAD LABORATORIES, INC. (BIO)
BIO-RAD LABORATORIES, INC. (BIO)